18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

The 18th Shanghai Breast Reconstruction Conference was held in Shanghai on October 14–15, 2026. The meeting brought together renowned experts from the United States, France, Australia, Germany, the United Kingdom, and other countries and regions to share advanced experience and the latest research in breast reconstruction, specialist training, and interdisciplinary collaboration.
18th Shanghai Breast Reconstruction Conference | Professor Jiong Wu: Focusing on Cutting-Edge Techniques and International Collaboration to Advance Breast Reconstruction

18th Shanghai Breast Reconstruction Conference | Professor Jiong Wu: Focusing on Cutting-Edge Techniques and International Collaboration to Advance Breast Reconstruction

The 18th Shanghai Breast Reconstruction Conference, jointly organized by the Shanghai Anti-Cancer Association and the Shanghai Foundation for Cancer Prevention and Treatment, guided by the Breast Cancer Committee of the Chinese Anti-Cancer Association, and hosted by Fudan University Shanghai Cancer Center, was held in Shanghai from October 10 to 14, 2026. Under the theme “Global Wisdom, Collaborative Practice,” the conference embraced the principles of innovation, cooperation, and development, presenting a high-level, international, and multidisciplinary academic event.
SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

As more patients with breast cancer seek both oncologic cure and preservation of breast appearance, breast-conserving surgery and breast reconstruction have become increasingly important components of comprehensive breast cancer care. The challenge is to improve aesthetic outcomes and quality of life while maintaining oncologic safety, ensuring effective local control, and minimizing long-term risks. This requires individualized, multidisciplinary surgical decision-making. At the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Symposium (SIBCS), Professor Liang Huang of Fudan University Shanghai Cancer Center spoke with Oncology Frontier about balancing oncologic safety and aesthetic outcomes in breast-conserving surgery and reconstruction, selecting techniques for Chinese women with distinct breast anatomy, weighing implant-based against autologous tissue reconstruction, and the roles of multidisciplinary team (MDT) collaboration and patient communication.
Ask the Experts | Breast Cancer: Professor Shunrong Li — Is Breast Reconstruction After Surgery “The Finishing Touch” or an Essential Part of Treatment?

Ask the Experts | Breast Cancer: Professor Shunrong Li — Is Breast Reconstruction After Surgery “The Finishing Touch” or an Essential Part of Treatment?

Every October, Breast Cancer Awareness Month, widely known as “Pink Ribbon Month,” returns to raise awareness. Supported by healthcare organizations and public interest groups around the world, this initiative aims to improve public understanding of breast cancer, promote early screening, diagnosis, and treatment, and highlight the importance of long-term quality of life for survivors. With rapid advances in systemic therapies and surgical techniques, the goals of breast cancer treatment have evolved beyond simply prolonging survival to include quality of life and a sense of bodily wholeness. As an important component of comprehensive breast cancer care, breast reconstruction can restore physical appearance while also having a profound impact on patients’ psychological well-being, family relationships, and social functioning.
A Global ADC Industry Milestone: SystImmune and Biotech Company Sichuan Biokin Win a Prestigious World ADC Award

A Global ADC Industry Milestone: SystImmune and Biotech Company Sichuan Biokin Win a Prestigious World ADC Award

On October 14, 2026, the 17th World ADC San Diego conference, currently taking place in San Diego, USA, announced this year's World ADC Awards. Iza-bren (lunvenlatug vedotin; Yizekang®, BL-B01D1), a first-in-class, new-concept bispecific antibody–drug conjugate (ADC) independently developed by Sichuan Biokin Pharmaceutical and currently the world's first and only approved EGFR×HER3 bispecific ADC, was named Best ADC Clinical Impact Winner.
SIERRA Study Primary Analysis Published Online in the Journal of Hepatology, Providing New Evidence of a Favorable Risk–Benefit Profile for Patients with Unresectable HCC and Poor Prognostic Factors

SIERRA Study Primary Analysis Published Online in the Journal of Hepatology, Providing New Evidence of a Favorable Risk–Benefit Profile for Patients with Unresectable HCC and Poor Prognostic Factors

Hepatocellular carcinoma (HCC) represents a major global health burden, with unresectable HCC (uHCC) accounting for a substantial proportion of cases and carrying a poor prognosis. Pivotal phase III clinical trials in uHCC have generally excluded patients with poor prognostic factors, including impaired liver function (e.g., Child-Pugh class B/C), poor performance status (ECOG performance status [PS] >1), or main trunk portal vein tumor thrombosis (Vp4). In clinical practice, these patients account for as much as 65% of the uHCC population. In recent years, combination immunotherapy has become a standard first-line treatment approach for uHCC. The HIMALAYA study established the first-line value of the STRIDE regimen, comprising a single priming dose of tremelimumab followed by maintenance durvalumab. However, HIMALAYA likewise enrolled only patients with Child-Pugh class A liver function, ECOG PS 0–1, and no Vp4 involvement. Because patients with these poor prognostic factors have been underrepresented in global phase III trials, high-level evidence to guide treatment decisions remains limited, making clinical management particularly challenging.
Between the Meridians | SIBCS Special: Professor Shusen Wang on Key Clinical Decision-Making in Breast Cancer—Advancing Subtype-Based Treatment and Standardized Care

Between the Meridians | SIBCS Special: Professor Shusen Wang on Key Clinical Decision-Making in Breast Cancer—Advancing Subtype-Based Treatment and Standardized Care

The 19th National Breast Cancer Academic Conference and the 21st Shanghai International Breast Cancer Symposium (SIBCS) were successfully held on October 16–17. Under the theme “Building on Solid Foundations and Navigating with Precision,” this year's meeting focused on advances in breast cancer diagnosis and treatment. At the conference, Professor Shusen Wang of the Breast Cancer Prevention and Treatment Center, Sun Yat-sen University Cancer Center, served as an expert in the late-stage disease section of the Chinese Anti-Cancer Association Guidelines and Standards for Breast Cancer Diagnosis and Treatment. He joined fellow experts in analyzing, reviewing, and discussing challenging cases of advanced breast cancer. Against this background, Oncology Frontier invited Professor Wang to share his insights on patient selection and key clinical decision-making, the integration of treatment recommendations in clinical guidelines with individualized care, and the challenges and potential pathways for implementing guidelines in routine practice.
Professor Jun Ma, Chair of the Chinese Anti-Cancer Association’s Nasopharyngeal Carcinoma Committee, Elected to the U.S. National Academy of Medicine

Professor Jun Ma, Chair of the Chinese Anti-Cancer Association’s Nasopharyngeal Carcinoma Committee, Elected to the U.S. National Academy of Medicine

According to the list of newly elected members for 2026 released by the U.S. National Academy of Medicine (NAM) on the 19th local time, Academician Jun Ma of the Chinese Academy of Sciences, Chair of the Nasopharyngeal Carcinoma Committee of the Chinese Anti-Cancer Association, and Executive Vice President of Sun Yat-sen University Cancer Center, has been elected to the NAM. He is the only scholar from China among the international members elected this year.
Transformation Breakthroughs | Episode 4: Maintaining the Safety Threshold—Toxicity and Comprehensive Management of Immunotherapy Combined with Surgery Through the Lens of TALENTOP

Transformation Breakthroughs | Episode 4: Maintaining the Safety Threshold—Toxicity and Comprehensive Management of Immunotherapy Combined with Surgery Through the Lens of TALENTOP

On August 22, 2026, the phase III TALENTOP study, led by Academician Jia Fan and conducted across 24 centers nationwide, was published in The Lancet, a leading international medical journal. The study provides high-level Chinese clinical evidence for conversion therapy in advanced hepatocellular carcinoma (HCC) and redefines the boundaries of surgical treatment for advanced HCC. These findings have attracted widespread academic attention in China and internationally.